Venetoclax and Ibrutinib in Treating Participants With High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well venetoclax and ibrutinib work in treating participants
with high-risk chronic lymphocytic leukemia/small lymphocytic lymphoma. Drugs used in
chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving venetoclax and ibrutinib may work better in treating
participants with chronic lymphocytic leukemia/small lymphocytic lymphoma.